Drug Profile
Research programme: diabetes and obesity therapeutics - Siragen Pharmaceuticals
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Siragen Pharmaceuticals
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Diabetes mellitus; Obesity
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 28 Aug 2020 No recent reports of development identified for research development in Obesity in USA
- 08 Jul 2016 Research programme: diabetes and obesity therapeutics - Siragen Pharmaceuticals is available for licensing as of 08 Jul 2016. https://siragen.com/